• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

造血干细胞移植对年轻镰状细胞病患者心肌纤维化的影响。

Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.

机构信息

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.

Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.

出版信息

Blood. 2024 Aug 8;144(6):672-675. doi: 10.1182/blood.2023023028.

DOI:10.1182/blood.2023023028
PMID:38691679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11347799/
Abstract

Serial cardiovascular magnetic resonance evaluation of children and young adults with SCD who underwent hematopoietic cell transplantation showed mean ECV, representing diffuse myocardial fibrosis, decreased 3.4% from baseline to 12 months posttransplantation. This trial was registered at www.clinicaltrials.gov as #NCT04362293.

摘要

对接受造血细胞移植的 SCD 儿童和青年进行的连续心血管磁共振评估显示，代表弥漫性心肌纤维化的平均 ECV 值从基线到移植后 12 个月下降了 3.4%。这项试验在 www.clinicaltrials.gov 上注册为 #NCT04362293。

相似文献

1
Impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease.造血干细胞移植对年轻镰状细胞病患者心肌纤维化的影响。
Blood. 2024 Aug 8;144(6):672-675. doi: 10.1182/blood.2023023028.
2
Laser therapy for retinopathy in sickle cell disease.激光疗法治疗镰状细胞病视网膜病变。
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.
3
Laser therapy for retinopathy in sickle cell disease.镰状细胞病视网膜病变的激光治疗
Cochrane Database Syst Rev. 2015 Oct 9;2015(10):CD010790. doi: 10.1002/14651858.CD010790.pub2.
4
Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications.针对患者及护理人员的干预措施，以提高对镰状细胞病的认识及其相关并发症的识别能力。
Cochrane Database Syst Rev. 2016 Oct 6;10(10):CD011175. doi: 10.1002/14651858.CD011175.pub2.
5
Interventions for chronic kidney disease in people with sickle cell disease.镰状细胞病患者慢性肾脏病的干预措施。
Cochrane Database Syst Rev. 2017 Jul 3;7(7):CD012380. doi: 10.1002/14651858.CD012380.pub2.
6
Folate supplementation in people with sickle cell disease.镰状细胞病患者的叶酸补充
Cochrane Database Syst Rev. 2018 Mar 16;3(3):CD011130. doi: 10.1002/14651858.CD011130.pub3.
7
Pulmonary Function after Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.非清髓性造血细胞移植治疗镰状细胞病后的肺功能。
Ann Am Thorac Soc. 2024 Oct;21(10):1398-1406. doi: 10.1513/AnnalsATS.202309-771OC.
8
Exagamglogene Autotemcel for Severe Sickle Cell Disease.依洛尤单抗治疗严重镰状细胞病。
N Engl J Med. 2024 May 9;390(18):1649-1662. doi: 10.1056/NEJMoa2309676. Epub 2024 Apr 24.
9
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.镰状细胞病青少年和青年患者造血细胞移植与标准治疗的比较。
Blood Adv. 2025 Mar 11;9(5):955-965. doi: 10.1182/bloodadvances.2024013926.
10
Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease.镰状细胞病异基因匹配相关供者造血细胞移植所用方案的比较。
Transplant Cell Ther. 2025 Aug;31(8):594.e1-594.e13. doi: 10.1016/j.jtct.2025.05.004. Epub 2025 May 14.

引用本文的文献

1
A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease.镰状细胞病根治性治疗后统一、全面长期随访的路线图。
Blood Adv. 2025 Jun 24;9(12):3090-3103. doi: 10.1182/bloodadvances.2024013953.
2
How I treat sickle cell disease with gene therapy.我如何用基因疗法治疗镰状细胞病。
Blood. 2024 Dec 26;144(26):2693-2705. doi: 10.1182/blood.2024024519.

本文引用的文献

1
Determinants of ventricular arrhythmias in sickle cell anemia: toward better prevention of sudden cardiac death.影响镰状细胞贫血患者室性心律失常的因素：更好地预防心源性猝死。
Blood. 2023 Aug 3;142(5):409-420. doi: 10.1182/blood.2022019571.
2
Replacement substance P reduces cardiac fibrosis in monkeys with type 2 diabetes.替代物质 P 可减少 2 型糖尿病猴的心脏纤维化。
Biomed Pharmacother. 2023 Apr;160:114365. doi: 10.1016/j.biopha.2023.114365. Epub 2023 Feb 7.
3
Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients.多参数心脏磁共振在镰状细胞病患者中的预后价值。
Ann Hematol. 2023 Feb;102(2):261-270. doi: 10.1007/s00277-022-05057-6. Epub 2022 Dec 2.
4
Diffuse myocardial fibrosis occurs in young patients with sickle cell anemia despite early disease-modifying therapy.尽管早期采用了疾病改善疗法，但镰状细胞贫血的年轻患者仍会出现弥漫性心肌纤维化。
Blood. 2023 Mar 16;141(11):1358-1362. doi: 10.1182/blood.2022018209.
5
Diffuse myocardial fibrosis as an SCD biomarker.弥漫性心肌纤维化作为心源性猝死的生物标志物。
Blood. 2022 Sep 15;140(11):1191-1192. doi: 10.1182/blood.2022017725.
6
Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia.早期开始疾病修饰治疗可以阻止或预防镰状细胞贫血的弥漫性心肌纤维化。
Blood. 2022 Sep 15;140(11):1322-1324. doi: 10.1182/blood.2021015303.
7
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.弥漫性心肌纤维化：机制、诊断与治疗方法。
Nat Rev Cardiol. 2021 Jul;18(7):479-498. doi: 10.1038/s41569-020-00504-1. Epub 2021 Feb 10.
8
Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy.高血压合并心肌病小鼠模型中心肌肥厚和心肌纤维化的进展和消退。
J Cardiovasc Magn Reson. 2020 Aug 6;22(1):57. doi: 10.1186/s12968-020-00655-7.
9
Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity.镰状细胞贫血症中的左心房功能障碍与弥漫性心肌纤维化、右心室压力升高和运动能力降低有关。
Sci Rep. 2020 Feb 4;10(1):1767. doi: 10.1038/s41598-020-58662-8.
10
Myocardial Tissue Characterization and Fibrosis by Imaging.心肌组织的影像学特征与纤维化
JACC Cardiovasc Imaging. 2020 May;13(5):1221-1234. doi: 10.1016/j.jcmg.2019.06.030. Epub 2019 Sep 18.